Loading
MDD Is Suspected to Have the Greatest Burden of Diseases By 2030 / Major Depressive Disorder, Bipolar Disorder, Other Depressive Disorders · Observational Study
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned observational case-control study comparing kynurenine pathway metabolites between 45 patients with depressive disorders and 45 healthy controls. No results have been posted in this registry record; the study is not yet recruiting and represents an early-stage investigation of the kynurenine hypothesis in major depressive disorder.
Observational. MDD is Suspected to Have the Greatest Burden of Diseases by 2030, Major Depressive Disorder, Bipolar Disorder, Other Depressive Disorders; age from 18 Years; to 18 Years; accepts healthy volunteers. Intervention: Psychological and laboratory assessment of kynurenine pathway metabolites. Compared with: Healthy control group. n = 90. Sohag University Hospital, Egypt.
This is a planned observational case-control study comparing kynurenine pathway metabolites between 45 patients with depressive disorders and 45 healthy controls. No results have been posted in this registry record; the study is not yet recruiting and represents an early-stage investigation of the kynurenine hypothesis in major depressive disorder.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This study cannot yet inform clinical practice because results are not posted. Once data are available, kynurenine metabolite profiles may help understand the biochemical basis of depression, but a single small case-control study would not change treatment approaches without replication and mechanistic validation.
This is an observational case-control study registration with no posted results; it describes planned enrollment and outcome measures only, making it early-stage and hypothesis-generating until data are reported.
As stated by the source record.
Quoted from the source exactly as published.
This study cannot yet inform clinical practice because results are not posted. Once data are available, kynurenine metabolite profiles may help understand the biochemical basis of depression, but a single small case-control study would not change treatment approaches without replication and mechanistic validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07771517). This is a study registration, not published results. Lead sponsor: Sohag University. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 90 participants (ESTIMATED). Conditions: MDD is Suspected to Have the Greatest Burden of Diseases by 2030, Major Depressive Disorder, Bipolar Disorder, Other Depressive Disorders. Primary outcome measures: Psychological assessment of patients with depressive disorders , From the enrollment of all cases till three months later; Detect abnormalities in kynurenine pathway in patients with depressive disorders , From the time of enrollment till 3 months later. Brief summary: This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.